Insider trader in bapineuzumab case gets 9-year sentence
This article was originally published in Scrip
Executive Summary
The former hedge fund portfolio manager found guilty by a Manhattan federal jury in February for insider trading on study data involving Pfizer's and Johnson & Johnson's Alzheimer's drug bapineuzumab was sentenced on 8 September to nine years in federal prison.